| Outcome BMI category, kg/m2 |
Number of subjects | Apixaban events (%/year) |
Warfarin events (%/year) |
HR (95% CI) | Pinteraction | ||
|---|---|---|---|---|---|---|---|
| Stroke/SE | .11 | ||||||
| 18.5-<25 | 4052 | 59 (1.65) | 83 (2.36) |
|
0.70 (0.50-0.97) | ||
| 25-<30 | 6702 | 84 (1.37) | 90 (1.47) |
|
0.93 (0.69-1.26) | ||
| 30-<35 | 4379 | 51 (1.20) | 53 (1.33) |
|
0.91 (0.62-1.34) | ||
| 35-<40 | 1774 | 7 (0.42) | 22 (1.32) |
|
0.31 (0.13-0.74) | ||
| ≥40 | 1006 | 8 (0.92) | 11 (1.04) |
|
0.88 (0.35-2.18) | ||
| All-Cause mortality | .44 | ||||||
| 18.5-<25 | 4052 | 188 (5.11) | 210 (5.78) |
|
0.89 (0.73-1.08) | ||
| 25-<30 | 6702 | 212 (3.38) | 218 (3.48) |
|
0.97 (0.80-1.17) | ||
| 30-<35 | 4379 | 114 (2.63) | 143 (3.50) |
|
0.75 (0.59-0.96) | ||
| 35-<40 | 1774 | 40 (2.36) | 49 (2.88) |
|
0.82 (0.54-1.24) | ||
| ≥40 | 1006 | 27 (3.00) | 28 (2.61) |
|
1.15 (0.68-1.96) | ||
| Composite endpoint* | .20 | ||||||
| 18.5-<25 | 4052 | 234 (6.55) | 277 (7.91) |
|
0.83 (0.70-0.99) | ||
| 25-<30 | 6702 | 296 (4.84) | 303 (4.97) |
|
0.97 (0.83-1.14) | ||
| 30-<35 | 4379 | 171 (4.05) | 189 (4.75) |
|
0.85 (0.69-1.05) | ||
| 35-<40 | 1774 | 48 (2.85) | 73 (4.41) |
|
0.65 (0.45-0.93) | ||
| ≥40 | 1006 | 37 (4.25) | 40 (3.78) |
|
1.12 (0.72-1.76) | ||
| Major bleed | .039 | ||||||
| 18.5-<25 | 4035 | 72 (2.22) | 147 (4.70) |
|
0.47 (0.36-0.63) | ||
| 25-<30 | 6687 | 115 (2.04) | 156 (2.82) |
|
0.73 (0.57-0.92) | ||
| 30-<35 | 4366 | 88 (2.26) | 100 (2.76) |
|
0.82 (0.62-1.09) | ||
| 35-<40 | 1764 | 33 (2.16) | 35 (2.36) |
|
0.92 (0.57-1.48) | ||
| ≥40 | 1004 | 11 (1.38)) | 18 (1.85) |
|
0.74 (0.35-1.57) | ||
Favors apixaban
Favors warfarin
